Buyer’s Checklist for AI Clinical Tools in Senior Care
Evaluate an AI clinical tool the way you would evaluate a clinical protocol, not the way you would evaluate software. Require written answers to questions across groups — clinical boundary, validation evidence, workflow and alert burden, data and integration, governance and accountability, and contractual terms — and treat any refusal to answer in writing as an answer.
On this page
Two questions separate serious vendors from confident ones: what is the alert burden per nurse per shift, and who is accountable when a signal fires and nothing happens. Ask them of SeniorCRE too; our answers are on this page.
Key points
- Ask for written answers across six areas: the clinical boundary (does it diagnose or prompt), validation evidence (population, setting, and whether performance was measured outside the development site), workflow and alert burden (alerts per nurse per shift and the kill switch), data and integration (which systems, what latency, whose data), governance (who owns thresholds and how changes are log…
- The right number is one your clinical leadership agrees to in advance and can sustain, expressed per nurse per shift and monitored after go-live. What matters is less the specific number than whether the vendor will commit to a budget, measure against it, and reduce sensitivity if the budget is exceeded. A vendor unwilling to name a budget is transferring alert-fatigue risk to your nurses.
- Read the output language. Decision support prompts an assessment and shows the observations behind the prompt. A diagnostic claim names a condition, asserts a severity, or implies an action. If marketing says "detects sepsis" while the product says "assess this resident," the marketing is the problem and the contract should reflect the product.
- Ask for the population and setting the model was developed in, whether performance was evaluated in a setting other than the development site, how documentation and vitals cadence affect performance, and what happens when inputs are missing. Published sepsis-prediction evaluations show performance degrades when transferred across populations and documentation patterns, so development-site metrics…
- SeniorCRE clinical intelligence is decision support only, reproduces the operator\u2019s own screening criteria rather than authoring clinical criteria, publishes no clinical outcome or dollar-value claim, and as of $ is exercised in SeniorCRE validation environments rather than operator production with no completed operator pilot to cite. Alert-burden budgets, named signal ownership, and documen…
- Yes, where it can be. Alert-burden budgets, threshold-change notification, audit rights over signal logs, data return on exit, and the explicit statement that the tool is decision support and not a diagnostic device belong in the agreement rather than in a slide.
Frequently asked questions
- What should you ask a vendor before buying an AI clinical tool?
- Ask for written answers across six areas: the clinical boundary (does it diagnose or prompt), validation evidence (population, setting, and whether performance was measured outside the development site), workflow and alert burden (alerts per nurse per shift and the kill switch), data and integration (which systems, what latency, whose data), governance (who owns thresholds and how changes are logged), and contract terms (indemnity, audit rights, exit and data return). Our published checklist contains $ specific questions.
- What is a reasonable alert burden?
- The right number is one your clinical leadership agrees to in advance and can sustain, expressed per nurse per shift and monitored after go-live. What matters is less the specific number than whether the vendor will commit to a budget, measure against it, and reduce sensitivity if the budget is exceeded. A vendor unwilling to name a budget is transferring alert-fatigue risk to your nurses.
- How do you tell decision support from a diagnostic claim?
- Read the output language. Decision support prompts an assessment and shows the observations behind the prompt. A diagnostic claim names a condition, asserts a severity, or implies an action. If marketing says "detects sepsis" while the product says "assess this resident," the marketing is the problem and the contract should reflect the product.
- What validation evidence should you require?
- Ask for the population and setting the model was developed in, whether performance was evaluated in a setting other than the development site, how documentation and vitals cadence affect performance, and what happens when inputs are missing. Published sepsis-prediction evaluations show performance degrades when transferred across populations and documentation patterns, so development-site metrics alone are not evidence for your building.
- What are SeniorCRE’s own answers to this checklist?
- SeniorCRE clinical intelligence is decision support only, reproduces the operator\u2019s own screening criteria rather than authoring clinical criteria, publishes no clinical outcome or dollar-value claim, and as of $ is exercised in SeniorCRE validation environments rather than operator production with no completed operator pilot to cite. Alert-burden budgets, named signal ownership, and documented kill switches are non-optional parts of the design.
- Should the checklist be part of the contract?
- Yes, where it can be. Alert-burden budgets, threshold-change notification, audit rights over signal logs, data return on exit, and the explicit statement that the tool is decision support and not a diagnostic device belong in the agreement rather than in a slide.
https://seniorcre.com/clinical-intelligence/ai-clinical-tools-buyers-checklist